# Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism

> **NCT00465751** · EARLY_PHASE1 · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 30 (actual)

## Conditions studied

- Metabolic Syndrome
- Familial Hypertriglyceridemia
- Familial Combined Hyperlipidemia

## Interventions

- **DRUG:** chenodeoxycholic acid
- **DRUG:** placebo capsules

## Key facts

- **NCT ID:** NCT00465751
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00465751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00465751, "Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00465751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*